R&D Trends

Johnson & Johnson opens London Innovation Center

Friday, June 7, 2013 01:49 PM

Johnson & Johnson has opened the J&J Innovation Center in London, one of four regional hubs being established this year.  The goal of the Innovation Center is to accelerate early stage science and advance the development of new healthcare solutions.

More... »

Neurelis, Biotie Therapies partners, with acquisition option

Thursday, June 6, 2013 01:46 PM

Pharmaceutical company Neurelis has signed an agreement with Biotie Therapies, a specialized drug development company, to develop intranasal diazepam (NRL-1) and provide Biotie with the exclusive option, but not the obligation, to acquire all outstanding shares of Neurelis.

More... »

MorphoSys, GSK ink license agreement

Thursday, June 6, 2013 01:35 PM

Pharmaceutical developer MorphoSys has entered into a global agreement with GlaxoSmithKline to develop and commercialize MOR103, MorphoSys's proprietary HuCAL-derived antibody against GM-CSF, which has concluded phase I/II development in mild to moderate rheumatoid arthritis.

More... »

Pfizer, UCSF partner to expand drug discovery capabilities

Thursday, June 6, 2013 10:22 AM

Pfizer has expanded its Centers for Therapeutic Innovation (CTI), which is dedicated to establishing partnerships with academic medical centers, into the development of small-molecule drug candidates through a partnership with the University of California, San Francisco (UCSF). This partnership provides investigators from UCSF with access to Pfizer's small-molecule drug development capabilities, working with Pfizer scientists with the goal of jointly translating basic research into drug candidates to bring new therapies to patients.

More... »

MJFF launches $10 million programs for Parkinson’s research

Wednesday, June 5, 2013 01:40 PM

Michael J. Fox Foundation for Parkinson's Research (MJFF) has committed up to $10 million to its next funding round for the Edmond J. Safra Core Programs for PD research to prioritize research toward transformative treatments and a cure for Parkinson's disease (PD).

More... »

Japan screening massive drug compound libraries for new treatments

Wednesday, June 5, 2013 01:32 PM

The Global Health Innovative Technology Fund (GHIT Fund), a public-private partnership focused on Japanese R&D related to infectious disease, will make a series of agreements to screen compound libraries at Japanese pharmaceutical companies and research institutes for new treatments for malaria, tuberculosis and other afflictions.

More... »

Sanford-Burnham, Pfizer collaborate to speed drug discovery

Wednesday, June 5, 2013 01:18 PM

Sanford-Burnham Medical Research Institute has partnered with Pfizer as part of Pfizer's focus on translational medicine. The Centers for Therapeutic Innovation (CTI) is Pfizer’s research unit dedicated to establishing global partnerships with academic research institutions.

More... »

Indiana Biosciences Research Institute opens doors

Friday, May 31, 2013 11:18 AM

The new Indiana Biosciences Research Institute opened its doors as the first industry-led collaborative life sciences research institute in the U.S.

More... »

Biogen Idec, WPI to develop programs for BETC

Friday, May 31, 2013 10:50 AM

Global biotechnology company Biogen Idec has signed a collaboration agreement with Worcester Polytechnic Institute (WPI) to develop and deliver programs at the university’s Biomanufacturing Education and Training Center (BETC) of Worcester, Mass.

More... »

LLS, Valor Biotherapeutics partner to advance novel therapy

Thursday, May 30, 2013 04:18 PM

The Leukemia & Lymphoma Society (LLS), a global voluntary health agency,  is committing approximately $6 million to Valor Biotherapeutics, a joint venture of biotechnology companies ImmunGene and Caliber, to co-fund the completion of preclinical development, manufacturing and a phase I clinical trial for a novel fusion protein that may change the poor outcomes faced by many patients with indolent lymphomas who do not respond to standard therapy with rituximab.

More... »